

Abacavir

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Solid: 300 mg tablet (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Aciclovir

Section	Indications
Antiherpes medicines Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt) Oral > Liquid: 200 mg per 5 mL Oral > Solid: 200 mg tablet	Zoster Varicella Herpes simplex infections

Atazanavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 30 mg (as hydrochloride); 60 mg (as hydrochloride)

Indications

Chronic hepatitis C

Daclatasvir + sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 60 mg + 400 mg

Indications

Chronic hepatitis C

Darunavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dasabuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 250 mg tablet

Indications

Chronic hepatitis C

Didanosine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir

Section

Antiretrovirals > Integrase inhibitors
Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Elbasvir + grazoprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

Indications

Chronic hepatitis C

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Entecavir

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 0.05 mg per mL
Oral > Solid: 0.5 mg; 1 mg

Indications

Chronic hepatitis B

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid: 50 mg + 20 mg granules
Oral > Solid > tablet: 100 mg + 40 mg

Indications

Chronic hepatitis C

Indinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections
Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 50 mg per 5 mL
Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Indications

Therapeutic equivalent to emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to emtricitabine + tenofovir for

Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Lopinavir + ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nelfinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 250 mg (as mesilate)

Oral > Other: 50 mg per g oral powder

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nevirapine

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Oseltamivir

Section

Other antivirals

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate);

75 mg capsule (as phosphate)

Indications

Influenza due to identified seasonal influenza virus

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Raltegravir

Section

Antiretrovirals > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ravidasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
Oral > Solid > tablet: 200 mg

Indications

Chronic hepatitis C

Ribavirin

Section

Other antivirals
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Viral haemorrhagic fever, not elsewhere classified

Chronic hepatitis C

Ritonavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Saquinavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg; 400 mg

Indications

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg

Indications

Chronic hepatitis C

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Tenofovir alafenamide

Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 25 mg

Indications

Chronic hepatitis B

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Chronic hepatitis B

Valaciclovir

Section

Antiherpes medicines

Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Valganciclovir

Section

Other antivirals

Oral > Liquid: 50 mg per mL powder for oral solution

Oral > Solid > tablet: 450 mg

Indications

Cytomegaloviral retinitis

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > tablet: 300 mg

Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified